Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mayur Garg

Showing results (71-80 of 83) with videos related to

Pageof 9
Sort By:
Digestive Diseases and Sciences|January 3, 2026
Trends in Length of Stay, Steroid Use and Colectomy Rates in Patients Admitted with Acute Severe Ulcerative Colitis: The Impact of Accelerated and Intensified Infliximab DosingRyan Bartlett, Mustafa Mohamedrashed, Saiumaeswar Yogakanthi, et al.
Alimentary Pharmacology & Therapeutics|January 10, 2025
Blood Group B May Reduce Risk of Rebleeding in Patients With Upper Gastrointestinal Haemorrhage due to Peptic Ulcer DiseaseSarah Taylor, Lynna Chen, Krishneel Dutt, et al.
JGH Open : an Open Access Journal of Gastroenterology and Hepatology|March 11, 2026
Rise in Admissions for Acute Severe Ulcerative Colitis at an Australian Health Service With a Culturally and Linguistically Diverse PopulationRyan Bartlett, Mustafa Mohamedrashed, Saiumaeswar Yogakanthi, et al.
Alimentary Pharmacology & Therapeutics|May 14, 2025
Real-World Effectiveness of Budesonide Orodispersible Tablets for Eosinophilic Oesophagitis: The Importance of Patience and EducationSarah Taylor, Emily Barwick, Varan Perananthan, et al.
Alimentary Pharmacology & Therapeutics|April 30, 2020
Review article: prevention, diagnosis and management of COVID-19 in the IBD patientAysha H Al-Ani, Ralley E Prentice, Clarissa A Rentsch, et al.
Digestive Diseases and Sciences|March 27, 2026
The SILVER Platter for Patients with Inflammatory Bowel Disease (IBD): An IBD Pharmacy Technician-Led Subcutaneous Biologic Home Delivery Service Is Associated with Sustained Improvement in Adherence and Active Health ManagementAndrew Leake, Maria Bishara, Sheng Wei Lo, et al.
Journal of Gastroenterology and Hepatology|October 10, 2025
IBD 2024: Charting a New Course in IBD Proceedings of the Takeda Symposium 22-23 November 2024 W Hotel, Brisbane, Queensland, AustraliaUma Mahadevan, Vipul Jairath, Jakob Begun, et al.
Gut|August 15, 2019
Imbalance of the renin-angiotensin system may contribute to inflammation and fibrosis in IBD: a novel therapeutic target?Mayur Garg, Simon G Royce, Chris Tikellis, et al.
BMJ Open|July 20, 2024
Switching from Dose-Intensified intravenous to SubCutaneoUS infliximab in Inflammatory Bowel Disease (DISCUS-IBD): protocol for a multicentre randomised controlled trialRobert D Little, Jo McKenzie, Ashish Srinivasan, et al.
The Lancet. Gastroenterology & Hepatology|September 5, 2024
Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trialMatthew C Choy, Christopher F D Li Wai Suen, Danny Con, et al.
Pageof 9

Showing results (71-80 of 83) with videos related to

Sort By:
Pageof 9
Digestive Diseases and Sciences|January 3, 2026
Trends in Length of Stay, Steroid Use and Colectomy Rates in Patients Admitted with Acute Severe Ulcerative Colitis: The Impact of Accelerated and Intensified Infliximab DosingRyan Bartlett, Mustafa Mohamedrashed, Saiumaeswar Yogakanthi, et al.
Alimentary Pharmacology & Therapeutics|January 10, 2025
Blood Group B May Reduce Risk of Rebleeding in Patients With Upper Gastrointestinal Haemorrhage due to Peptic Ulcer DiseaseSarah Taylor, Lynna Chen, Krishneel Dutt, et al.
JGH Open : an Open Access Journal of Gastroenterology and Hepatology|March 11, 2026
Rise in Admissions for Acute Severe Ulcerative Colitis at an Australian Health Service With a Culturally and Linguistically Diverse PopulationRyan Bartlett, Mustafa Mohamedrashed, Saiumaeswar Yogakanthi, et al.
Alimentary Pharmacology & Therapeutics|May 14, 2025
Real-World Effectiveness of Budesonide Orodispersible Tablets for Eosinophilic Oesophagitis: The Importance of Patience and EducationSarah Taylor, Emily Barwick, Varan Perananthan, et al.
Alimentary Pharmacology & Therapeutics|April 30, 2020
Review article: prevention, diagnosis and management of COVID-19 in the IBD patientAysha H Al-Ani, Ralley E Prentice, Clarissa A Rentsch, et al.
Digestive Diseases and Sciences|March 27, 2026
The SILVER Platter for Patients with Inflammatory Bowel Disease (IBD): An IBD Pharmacy Technician-Led Subcutaneous Biologic Home Delivery Service Is Associated with Sustained Improvement in Adherence and Active Health ManagementAndrew Leake, Maria Bishara, Sheng Wei Lo, et al.
Journal of Gastroenterology and Hepatology|October 10, 2025
IBD 2024: Charting a New Course in IBD Proceedings of the Takeda Symposium 22-23 November 2024 W Hotel, Brisbane, Queensland, AustraliaUma Mahadevan, Vipul Jairath, Jakob Begun, et al.
Gut|August 15, 2019
Imbalance of the renin-angiotensin system may contribute to inflammation and fibrosis in IBD: a novel therapeutic target?Mayur Garg, Simon G Royce, Chris Tikellis, et al.
BMJ Open|July 20, 2024
Switching from Dose-Intensified intravenous to SubCutaneoUS infliximab in Inflammatory Bowel Disease (DISCUS-IBD): protocol for a multicentre randomised controlled trialRobert D Little, Jo McKenzie, Ashish Srinivasan, et al.
The Lancet. Gastroenterology & Hepatology|September 5, 2024
Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trialMatthew C Choy, Christopher F D Li Wai Suen, Danny Con, et al.
Pageof 9